Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study.

Abstract

In a 12-week placebo-controlled study of fluoxetine in the treatment of body dysmorphic disorder, the authors investigated change in psychosocial functioning and mental health-related quality of life in 60 subjects. The subjects were assessed with the LIFE-RIFT (a measure of impaired functioning), Social and Occupational Functioning Scale (SOFAS), and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) before and after receiving fluoxetine or placebo. At baseline, the patients had impaired psychosocial functioning and markedly poor mental health-related quality of life. Compared to placebo, fluoxetine was associated with significantly greater improvement in LIFE-RIFT and SOFAS scores and with improvement on the mental health subscale of the SF-36 that approached significance. Decrease in the severity of body dysmorphic disorder, as measured by the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, was significantly correlated with improvement in functioning and quality of life.

• Authors: Katharine A Phillips, Steven A Rasmussen
• Journal: Psychosomatics (Psychosomatics) 2004 Sep-Oct Vol. 45 Issue 5 Pg. 438-44 ISSN: 0033-3182 [Print] England
• PMID: 15345790 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Serotonin Uptake Inhibitors
• Fluoxetine

Topics

• Adult
• Double-Blind Method
• Female
• Fluoxetine (therapeutic use)
• Humans
• Male
• Quality of Life
• Selective Serotonin Reuptake Inhibitors (therapeutic use)
• Somatoform Disorders (drug therapy)